Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortTwice-a-year injection that prevents HIV.Backbone drug for HIV treatment, PrEP and hepatitis B.
Body systemAntiviralsAntivirals
Drug classHIV capsid inhibitorsNucleos(t)ide reverse transcriptase inhibitors
SupplyPrescription onlyPrescription onlyWHO essential medicine
Main usesHIV prevention (PrEP), Multidrug-resistant HIV treatment (with other drugs)HIV treatment, HIV pre-exposure prophylaxis (PrEP, with emtricitabine), Chronic hepatitis B
How it worksLocks HIV's protective shell so it can't unpack or rebuild.A fake DNA building block that stops HIV and hepatitis B copying themselves.
Starts working——
Half-life8–12 weeks after injectionAbout 17 hours in plasma
Typical adult dose927 mg by injection under the skin every 6 months, after a short oral loading phase.300 mg (245 mg tenofovir disoproxil) once a day.
FormsSubcutaneous injection, Tablet (start-up doses)Tablet, Combination tablets
Common side effectsInjection-site lumps, swelling or pain, Nausea, HeadacheNausea, Diarrhoea, Headache, Dizziness
Serious side effectsPersistent injection-site nodules, Resistance if HIV is acquired while levels are lowKidney damage, Bone thinning, Hepatitis B flare if stopped suddenly
Don't take if——
Alcohol——
PregnancyUse with cautionData are growing; trials included pregnancies without safety signals.Generally considered safeWidely used in pregnancy for HIV and hepatitis B.
Breastfeeding——
In use since20222001
Brand namesUnited States: Yeztugo (PrEP), Sunlenca (treatment)United Kingdom: SunlencaEurope: Yeytuo, SunlencaUnited States: Viread, Truvada (with emtricitabine)United Kingdom: Viread, TruvadaIndia: Tenvir
Legal status——
ATC code—J05AF07

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker